This CPI issue focuses primarily on two segments, product hopping and pay-for-delay. In the first piece, we look (1) “product hopping” from one version of a drug to another and (2) settlements by which brands pay generics to delay entry. Then, we look at regulatory approaches in the EU and U.S. on “evergreening,” FTC’s recent activities, and examine the growing interest outside the United States in getting into the “pay-for-delay” fray, how the Canadian competition authorities are dealing with the issue, how the Indian competition authority is looking at a pharma merger.
And in a special article, we join the debate that the USCC started by making antitrust fines officially a priority for 2015.
As always, thank you to our great panel of authors.